Another drug developer for the animal health field is going public. Parnell Pharmaceuticals outlined plans to raise $57.5 million in an IPO designed to fuel its work on new therapies for family pets as well as production animals. The Australian biotech--which set up an office in Overland Park, KS, a year ago--has run a slate of animal drug trials over the last decade, has 5 products on the market and is planning at least 25 more trials in the next four years. "Since launching in the U.S. in mid-2013, we have steadily acquired market share and we estimate that we typically enjoy a top three market share position in many other countries where we have been selling our products for many years," says the biotech. Among newly public animal health biotechs are Aratana Therapeutics ($PETX) and Kindred Biosciences ($KIN). S-1